MCK News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

MC

Mkt Cap

$101.98B

Volume

674.74K

Next Earnings

November 4th

Chart Financials Earnings News About Dividends Insider Filings

AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?AbbVie and Bristol Myers Squibb are compared as pharmaceutical investment options for 2026. AbbVie is recommended as the better buy due to its successful immunology franchise with Skyrizi and Rinvoq driving growth, diversification into aesthetics and neuroscience, and having navigated its patent cliff challenges. Bristol Myers Squibb, while cheaper on valuation metrics and maintaining strong profit margins, faces revenue stagnation, legal uncertainties from a Celgene acquisition lawsuit, and is still working through its own portfolio transition challenges.The Motley Fool · Sep 18, 2026

AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?The article compares AbbVie, a mature pharmaceutical company with stable cash flows and a growing immunology portfolio, against CRISPR Therapeutics, a clinical-stage biotech firm pioneering gene-editing therapies. AbbVie is recommended as the better choice for 2026 due to its profitability, strong free cash flow generation, and rising dividend, while CRISPR offers high-reward potential but faces significant cash burn and execution risks.The Motley Fool · Sep 14, 2026

Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?The article compares Amgen, an established biotech giant with $36.7B in revenue and strong profitability, against Revolution Medicines, a clinical-stage oncology company with no approved products but a breakthrough cancer therapy (Daraxonrasib) that showed 50%+ reduction in death risk for metastatic pancreatic cancer. The author recommends Revolution Medicines for long-term investors willing to accept biotech risk, citing the paradigm-shifting potential of its RAS-targeted cancer pipeline, despite current losses and competitive pressures.The Motley Fool · Sep 11, 2026

Cardinal (CAH) Up 2.5% Since Last Earnings Report: Can It Continue?Cardinal Health reported Q4 fiscal 2026 adjusted EPS of $2.91, beating consensus by 20.3%, with full-year adjusted EPS up 37% year-over-year. While revenues missed estimates, the company raised fiscal 2027 guidance to $12.40-$12.60 EPS, implying 13-15% growth. Shares have outperformed the S&P 500 over the past month, though the stock carries a Zacks Rank #3 (Hold) rating.Zacks Investment Research · Sep 10, 2026

Novocure Reports Patient Data Exposure in Cybersecurity IncidentNovocure Limited (NVCR) disclosed unauthorized access to internal systems in mid-August 2026, exposing internal patient ID numbers for over 1,400 U.S. patients and contact information for healthcare providers and employees. The company stated that medical devices were not accessed, systems remained functional, and no material financial impact is expected. NVCR shares rose 3.2% since the September 1 disclosure.Zacks Investment Research · Sep 7, 2026

AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?AbbVie has successfully diversified beyond its blockbuster Humira with strong immunology drugs (Skyrizi and Rinvoq), while Pfizer is leveraging its cash position to build oncology and GLP-1 pipelines. Despite AbbVie's stronger growth trajectory, Pfizer offers better valuation metrics with lower P/E and P/S ratios, making it the preferred choice for long-term value investors willing to wait for new product launches.The Motley Fool · Sep 4, 2026

Cencora Raises 2026 EPS Outlook as Specialty Businesses StrengthenCencora (COR) raised its fiscal 2026 adjusted EPS guidance to $17.75-$17.95 following stronger-than-expected third-quarter results. The company's U.S. segment profit grew 15.9% driven by specialty sales and GLP-1 demand, while international operating income rose 20.8%. However, headwinds from lower-margin GLP-1 products, manufacturer price reductions, and higher financing costs tempered upside. The stock maintains a Zacks Rank #3 (Hold) rating.Zacks Investment Research · Sep 3, 2026

Is Generics Still a Quiet Profit Engine for Cardinal Health?Cardinal Health's generics business continues to be a steady profit contributor, with fiscal 2026 volume growth exceeding long-term planning assumptions of 2-3%. The company expects fiscal 2027 to benefit from new generic launches, brand-to-generic conversions, and stable Red Oak program dynamics, supporting projected Pharma segment profit growth of 8-11%. Peers McKesson and Cencora also show strength in their pharmaceutical distribution and generics portfolios.Zacks Investment Research · Sep 3, 2026

Here's How Much a $1000 Investment in McKesson Made 10 Years Ago Would Be Worth TodayA $1,000 investment in McKesson (MCK) made in September 2016 would be worth $4,795.36 as of September 1, 2026, representing a 379.54% gain and significantly outperforming the S&P 500's 254.05% return. The pharmaceutical distributor is benefiting from growth in specialty pharmaceuticals, oncology services, and GLP-1 medications, with FY26 revenues reaching $403.4 billion and adjusted EPS up 18% year-over-year. Analysts remain optimistic with recent earnings estimate revisions and raised fiscal 2027 guidance.Zacks Investment Research · Sep 1, 2026

McKesson Corporation: Ademi LLP Investigates Claims for DamagesMcKesson disclosed a data breach on August 25, 2026, affecting 284 million records belonging to tens of millions of patients. Compromised information includes personal identities, healthcare identifiers, medical records, prescription data, and highly sensitive health information. Ademi LLP is investigating potential data privacy claims and advising affected individuals to monitor financial accounts and consider credit protection measures.GlobeNewswire Inc. · Aug 29, 2026

MC

MCKMcKesson Corporation

MCK

Pay with—

Available Balance0.00

Your PositionYou don't own any MCK yet.

Related Tickers

Earnings

Dividends

Last · Sep 1Quarterly

Amount$0.94

Yield0.43%

Annual$3.76